Chromadex Corp CS (CDXC) 2.84 $CDXC
IMPORTANT SHAREHOLDER NOTICE: Goldberg Law PC Announces An Investigation of Claims Against ChromaDex Corporation And Advises Investors With Losses To Contact The Firm
BusinessWire - Mon Jun 20, 7:23PM CDT
Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by ChromaDex Corporation ("ChromaDex" or the "Company"
(Nasdaq: CDXC). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
CDXC: 2.84 (-2.14)
ChromaDex Names Former Chairman & CEO of The Quaker Oats Company, William Smithburg, to its Board of Directors
GlobeNewswire - Tue Jun 07, 5:30AM CDT
ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that William Smithburg has joined the Company's board of directors as an independent director.
ABT: 37.75 (+0.36), CDXC: 2.84 (-2.14)
ChromaDex Announces $5.25 Million Registered Direct Offering
GlobeNewswire - Mon Jun 06, 5:30AM CDT
ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that it has entered into an agreement with one investor to purchase $5.25 million of the Company's common stock in a registered direct offering. The fees associated with this transaction were minimal as no underwriter or placement agent was used in the offering.
CDXC: 2.84 (-2.14)
University Researchers Show Vitamin Nicotinamide Riboside is an Effective Tool for Managing the Negative Effects of Obesity and Diabetes
GlobeNewswire - Wed Jun 01, 5:30AM CDT
ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that researchers from the University of Iowa found a way to reduce the risks of developing insulin resistance and sensory neuropathy (nerve damage) in mice with induced prediabetes and type 2 diabetes, using ChromaDex's nicotinamide riboside (NR), NIAGEN, which is a form of vitamin B3. The results of this study, published in the journal Scientific Reports, demonstrate that NR was successful at reducing fasting and non-fasting blood glucose levels, as well as weight gain, and was protective against sensory neuropathy in these groups.
CDXC: 2.84 (-2.14)
ChromaDex to Present at the 2016 Marcum MicroCap Conference on June 1, 2016
GlobeNewswire - Wed May 25, 5:30AM CDT
ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today its Chief Financial Officer, Tom Varvaro, will present at the 2016 Marcum MicroCap Conference. The investor conference will be held on June 1-2, 2016 at the Grand Hyatt New York in New York, N.Y.
CDXC: 2.84 (-2.14)
ChromaDex to Present at the 17th Annual B. Riley & Co. Investor Conference on May 26, 2016
GlobeNewswire - Wed May 18, 5:30AM CDT
ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today its Chief Executive Officer and Founder, Frank Jaksch, will present at the 17 Annual B. Riley & Co. Investor Conference. The investor conference will be held on May 25-26, 2016 at the Loews Hollywood Hotel in Los Angeles, California.
CDXC: 2.84 (-2.14)
ChromaDex Names Will T. Black to its Executive Team as Vice President, Sales and Marketing
GlobeNewswire - Mon May 16, 5:30AM CDT
ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that Will Black has joined the company as Vice President of Sales and Marketing.
CDXC: 2.84 (-2.14)
ChromaDex Reports Record Revenue and Quarterly Net Income as Ingredients Sales Climb 72%
GlobeNewswire - Thu May 12, 5:30AM CDT
-Company Records Net Income of $256,000 as Company Reports Record Revenue of $7.3 Million-
CDXC: 2.84 (-2.14)
ChromaDex to Report First Quarter 2016 Financial Results on Thursday, May 12, 2016
GlobeNewswire - Tue May 10, 5:45AM CDT
ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that it plans on reporting its first quarter 2016 financial results on Thursday, May 12, before the open of the financial markets.
CDXC: 2.84 (-2.14)
Big Insider Moves at Majesco, Phillip Frost Discloses Major Insider Transaction
ACCESSWIRE - Mon May 09, 10:09AM CDT
NEW YORK, NY / ACCESSWIRE / May 9, 2016 / After picking up a new management team and additional board of directors, stagnant video gaming firm Majesco Entertainment Co. (NASDAQ:COOL) just landed key insider investments totalling 9.9% of shares outstanding as of May 9. Leading the aggressive accumulation is the legendary biotechnology investor Dr. Phillip Frost, CEO of Opko Health (NYSE:OPK) and former CEO of generics giant Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA).
YHOO: 37.29 (+0.35), COOL: 0.78 (-0.02), OPK: 9.19 (+0.14), CDXC: 2.84 (-2.14), TEVA: 51.97 (-0.04), MJCO: 5.11 (-0.01)
ChromaDex Corp. (Nasdaq: CDXC) to Ring The Nasdaq Stock Market Opening Bell
GlobeNewswire - Thu May 05, 9:00AM CDT
What:
CDXC: 2.84 (-2.14), NDAQ: 63.09 (-0.79)
ChromaDex to Present at the Drexel Hamilton Micro Cap Investor Forum on May 12, 2016
GlobeNewswire - Thu Apr 28, 5:30AM CDT
ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today its Chief Executive Officer and Founder, Frank Jaksch, will present at the Drexel Hamilton Micro Cap Investor Forum. The investor forum will be held on May 12, 2016 at the offices of Drexel Hamilton in New York, New York.
CDXC: 2.84 (-2.14)
ChromaDex to Begin Trading on The NASDAQ Capital Market Today
GlobeNewswire - Mon Apr 25, 5:30AM CDT
ChromaDex Corp. (NASDAQ:CDXC), formerly (OTCQX:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, today announced that the Company's common stock will be eligible to trade on The NASDAQ Capital Market under the symbol "CDXC" upon the open of the market today.
CDXC: 2.84 (-2.14)
ChromaDex Approved for Listing on The NASDAQ Capital Market
GlobeNewswire - Thu Apr 21, 5:30AM CDT
-Company Will Begin Trading on NASDAQ on Monday, April 25, 2016-
CDXC: 2.84 (-2.14)
NECTAR7 Launches NIAGEN(R) & Collagen Dietary Supplement
GlobeNewswire - Tue Apr 19, 5:30AM CDT
ChromaDex Corp. (OTCQX:CDXCD) (OTCQX:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that NECTAR7 has released a new product, NIAGEN & COLLAGEN featuring ChromaDex's lead ingredient, NIAGEN.
CDXC: 2.84 (-2.14)
Thorne Research Announces Clinical Study to Assess Nicotinamide Riboside on Brain NAD+ in College Football Players
PR Newswire - Wed Apr 13, 8:05AM CDT
Thorne Research and ChromaDex Corp. (OTCQX: CDXC) announced today a research endeavor with Mayo Clinic and the University of Minnesota Clinical and Translational Science Institute, regarding a planned clinical study to assess the effect of Nicotinamide Riboside (NR) on brain NAD+ in college football players.
CDXC: 2.84 (-2.14)
ChromaDex Announces Reverse Stock Split as Company Seeks to List its Common Stock on The NASDAQ Capital Market
GlobeNewswire - Tue Apr 12, 3:05PM CDT
ChromaDex Corp. (OTCQX:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today a reverse stock split of its shares of common stock at a ratio of 1-for-3. At the market open on Wednesday, April 13, 2016, ChromaDex common stock will begin trading on a split-adjusted basis. The Company's common stock will trade under the ticker symbol "CDXCD" until the earlier of 20 trading days after the reverse split has been effected or listing on The NASDAQ Capital Market, after which the trading symbol will revert to "CDXC."
CDXC: 2.84 (-2.14)
ChromaDex Reports 2015 Record Revenue as Ingredient Sales Grew 83%
GlobeNewswire - Thu Mar 17, 3:44PM CDT
- Company Expects to Report Record Revenue for Q1 2016 -
CDXC: 2.84 (-2.14), PG: 83.04 (-0.09)
Analyzing the Price Movement - Analyst Research on American Green, Goodrich Petroleum, Anglo American and Chromadex
ACCESSWIRE - Tue Mar 15, 7:35AM CDT
NEW YORK, NY / ACCESSWIRE / March 15, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: American Green Inc. (OTC: ERBB), Goodrich Petroleum Corp. (OTC: GDPM), Anglo American PLC (OTC: NGLOY) and Chromadex Corp. (OTC: CDXC). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
CDXC: 2.84 (-2.14)
IMPORTANT SHAREHOLDER NOTICE: Goldberg Law PC Announces An Investigation of Claims Against ChromaDex Corporation And Advises Investors With Losses To Contact The Firm
BusinessWire - Mon Jun 20, 7:23PM CDT
Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by ChromaDex Corporation ("ChromaDex" or the "Company"
(Nasdaq: CDXC). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors. CDXC: 2.84 (-2.14)
ChromaDex Names Former Chairman & CEO of The Quaker Oats Company, William Smithburg, to its Board of Directors
GlobeNewswire - Tue Jun 07, 5:30AM CDT
ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that William Smithburg has joined the Company's board of directors as an independent director.
ABT: 37.75 (+0.36), CDXC: 2.84 (-2.14)
ChromaDex Announces $5.25 Million Registered Direct Offering
GlobeNewswire - Mon Jun 06, 5:30AM CDT
ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that it has entered into an agreement with one investor to purchase $5.25 million of the Company's common stock in a registered direct offering. The fees associated with this transaction were minimal as no underwriter or placement agent was used in the offering.
CDXC: 2.84 (-2.14)
University Researchers Show Vitamin Nicotinamide Riboside is an Effective Tool for Managing the Negative Effects of Obesity and Diabetes
GlobeNewswire - Wed Jun 01, 5:30AM CDT
ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that researchers from the University of Iowa found a way to reduce the risks of developing insulin resistance and sensory neuropathy (nerve damage) in mice with induced prediabetes and type 2 diabetes, using ChromaDex's nicotinamide riboside (NR), NIAGEN, which is a form of vitamin B3. The results of this study, published in the journal Scientific Reports, demonstrate that NR was successful at reducing fasting and non-fasting blood glucose levels, as well as weight gain, and was protective against sensory neuropathy in these groups.
CDXC: 2.84 (-2.14)
ChromaDex to Present at the 2016 Marcum MicroCap Conference on June 1, 2016
GlobeNewswire - Wed May 25, 5:30AM CDT
ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today its Chief Financial Officer, Tom Varvaro, will present at the 2016 Marcum MicroCap Conference. The investor conference will be held on June 1-2, 2016 at the Grand Hyatt New York in New York, N.Y.
CDXC: 2.84 (-2.14)
ChromaDex to Present at the 17th Annual B. Riley & Co. Investor Conference on May 26, 2016
GlobeNewswire - Wed May 18, 5:30AM CDT
ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today its Chief Executive Officer and Founder, Frank Jaksch, will present at the 17 Annual B. Riley & Co. Investor Conference. The investor conference will be held on May 25-26, 2016 at the Loews Hollywood Hotel in Los Angeles, California.
CDXC: 2.84 (-2.14)
ChromaDex Names Will T. Black to its Executive Team as Vice President, Sales and Marketing
GlobeNewswire - Mon May 16, 5:30AM CDT
ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that Will Black has joined the company as Vice President of Sales and Marketing.
CDXC: 2.84 (-2.14)
ChromaDex Reports Record Revenue and Quarterly Net Income as Ingredients Sales Climb 72%
GlobeNewswire - Thu May 12, 5:30AM CDT
-Company Records Net Income of $256,000 as Company Reports Record Revenue of $7.3 Million-
CDXC: 2.84 (-2.14)
ChromaDex to Report First Quarter 2016 Financial Results on Thursday, May 12, 2016
GlobeNewswire - Tue May 10, 5:45AM CDT
ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that it plans on reporting its first quarter 2016 financial results on Thursday, May 12, before the open of the financial markets.
CDXC: 2.84 (-2.14)
Big Insider Moves at Majesco, Phillip Frost Discloses Major Insider Transaction
ACCESSWIRE - Mon May 09, 10:09AM CDT
NEW YORK, NY / ACCESSWIRE / May 9, 2016 / After picking up a new management team and additional board of directors, stagnant video gaming firm Majesco Entertainment Co. (NASDAQ:COOL) just landed key insider investments totalling 9.9% of shares outstanding as of May 9. Leading the aggressive accumulation is the legendary biotechnology investor Dr. Phillip Frost, CEO of Opko Health (NYSE:OPK) and former CEO of generics giant Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA).
YHOO: 37.29 (+0.35), COOL: 0.78 (-0.02), OPK: 9.19 (+0.14), CDXC: 2.84 (-2.14), TEVA: 51.97 (-0.04), MJCO: 5.11 (-0.01)
ChromaDex Corp. (Nasdaq: CDXC) to Ring The Nasdaq Stock Market Opening Bell
GlobeNewswire - Thu May 05, 9:00AM CDT
What:
CDXC: 2.84 (-2.14), NDAQ: 63.09 (-0.79)
ChromaDex to Present at the Drexel Hamilton Micro Cap Investor Forum on May 12, 2016
GlobeNewswire - Thu Apr 28, 5:30AM CDT
ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today its Chief Executive Officer and Founder, Frank Jaksch, will present at the Drexel Hamilton Micro Cap Investor Forum. The investor forum will be held on May 12, 2016 at the offices of Drexel Hamilton in New York, New York.
CDXC: 2.84 (-2.14)
ChromaDex to Begin Trading on The NASDAQ Capital Market Today
GlobeNewswire - Mon Apr 25, 5:30AM CDT
ChromaDex Corp. (NASDAQ:CDXC), formerly (OTCQX:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, today announced that the Company's common stock will be eligible to trade on The NASDAQ Capital Market under the symbol "CDXC" upon the open of the market today.
CDXC: 2.84 (-2.14)
ChromaDex Approved for Listing on The NASDAQ Capital Market
GlobeNewswire - Thu Apr 21, 5:30AM CDT
-Company Will Begin Trading on NASDAQ on Monday, April 25, 2016-
CDXC: 2.84 (-2.14)
NECTAR7 Launches NIAGEN(R) & Collagen Dietary Supplement
GlobeNewswire - Tue Apr 19, 5:30AM CDT
ChromaDex Corp. (OTCQX:CDXCD) (OTCQX:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that NECTAR7 has released a new product, NIAGEN & COLLAGEN featuring ChromaDex's lead ingredient, NIAGEN.
CDXC: 2.84 (-2.14)
Thorne Research Announces Clinical Study to Assess Nicotinamide Riboside on Brain NAD+ in College Football Players
PR Newswire - Wed Apr 13, 8:05AM CDT
Thorne Research and ChromaDex Corp. (OTCQX: CDXC) announced today a research endeavor with Mayo Clinic and the University of Minnesota Clinical and Translational Science Institute, regarding a planned clinical study to assess the effect of Nicotinamide Riboside (NR) on brain NAD+ in college football players.
CDXC: 2.84 (-2.14)
ChromaDex Announces Reverse Stock Split as Company Seeks to List its Common Stock on The NASDAQ Capital Market
GlobeNewswire - Tue Apr 12, 3:05PM CDT
ChromaDex Corp. (OTCQX:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today a reverse stock split of its shares of common stock at a ratio of 1-for-3. At the market open on Wednesday, April 13, 2016, ChromaDex common stock will begin trading on a split-adjusted basis. The Company's common stock will trade under the ticker symbol "CDXCD" until the earlier of 20 trading days after the reverse split has been effected or listing on The NASDAQ Capital Market, after which the trading symbol will revert to "CDXC."
CDXC: 2.84 (-2.14)
ChromaDex Reports 2015 Record Revenue as Ingredient Sales Grew 83%
GlobeNewswire - Thu Mar 17, 3:44PM CDT
- Company Expects to Report Record Revenue for Q1 2016 -
CDXC: 2.84 (-2.14), PG: 83.04 (-0.09)
Analyzing the Price Movement - Analyst Research on American Green, Goodrich Petroleum, Anglo American and Chromadex
ACCESSWIRE - Tue Mar 15, 7:35AM CDT
NEW YORK, NY / ACCESSWIRE / March 15, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: American Green Inc. (OTC: ERBB), Goodrich Petroleum Corp. (OTC: GDPM), Anglo American PLC (OTC: NGLOY) and Chromadex Corp. (OTC: CDXC). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
CDXC: 2.84 (-2.14)
